Active, not recruitingPhase 3NCT03732677

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

Studying Muscular tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AstraZeneca
Intervention
Durvalumab(drug)
Enrollment
1063 enrolled
Eligibility
18-130 years · All sexes
Timeline
20182026

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03732677 on ClinicalTrials.gov

Other trials for Muscular tumor

Additional recruiting or active studies for the same condition.

See all trials for Muscular tumor

← Back to all trials